CKMSynced Forum
Embracing a holistic approach to DKD, CVD and CKM comorbidities with empagliflozin
The cardiovascular, kidney, and metabolic (CKM) systems are interconnected through complex and multifactorial interaction and neurohormonal feedback mechanisms. In this webinar, Dr. Janaka Karalliedde from the Guy’s and St Thomas’ Hospital, King’s College London, the United Kingdom, highlights the significance of recognizing and addressing all three conditions, type 2 diabetes mellitus (T2D), diabetic kidney disease (DKD) and heart failure (HF), as well as the impact of empagliflozin on renal outcomes, cardiovascular benefits and mortality risks.
Dr. Karalliedde further emphasized the need for early intervention and the role of primary care physicians in screening and treating patients early with sodium-glucose cotransporter 2 inhibitors (SGLT2is) such as empagliflozin to maximize the potential benefits of the drug on the CKM systems and patients’ quality of life.
This is an independent editorial material, published and distributed through unrestricted educational support from the pharmaceutical community, for the purpose of continuing medical education only. The views expressed in this publication reflect the experience and/or opinion of the author(s) and are not necessarily those of editors, publisher, and sponsor(s). Because of rapid advances in medicine, independent verification of clinical diagnoses, medical suitability and dosage should be made before treatment prescription. The appearance of advertisement, if any, has no influence on editorial content or presentation and does not imply the endorsement of products by the publication, or its authors and editors.
